Ventripoint Diagnostics (TSXV: VPT) this morning announced a major arrangement. The company has officially entered into a collaboration with that of GE Healthcare, a subsidiary of General Electric (NYSE: GE).
The collaboration will see Ventripoint included within GE’s Edison Developer Program as an innovator. The program is designed to help healthcare providers gain access to market-ready applications, with the program also expected to bring more functionality to the firms cardiac ultrasounds devices..
The arrangement will effectively see the installed base be enhanced for Ventripoint, while also driving commercial growth worldwide via access to GE’s global sales channels. These sales channels under the collaboration will also have the potential to see VPT’s advanced 3D image analysis tools used for studies.
“We are delighted to partner with GE Healthcare to work towards bringing our cardiac analysis tools to their existing customer base of cardiologists,”Dr. George Adams, Executive-Chairman of Ventripoint
Ventripoint Diagnostics last traded at $0.64 on the TSX Venture.
FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.